NYU Langone Health b\u00fcnyesindeki bilim insanlar\u0131, agresif seyreden deri kanseri melanoman\u0131n tedavisinde umut vadeden \u00f6nemli bir geli\u015fmeye imza att\u0131. Ara\u015ft\u0131rmac\u0131lar, hastalar\u0131n kan dola\u015f\u0131m\u0131nda bulunan t\u00fcm\u00f6r kaynakl\u0131 DNA par\u00e7ac\u0131klar\u0131n\u0131n (ctDNA) takibinin, kanserin n\u00fcks etme olas\u0131l\u0131\u011f\u0131n\u0131 y\u00fcksek do\u011frulukla tahmin edebilece\u011fini ortaya koydu. Bu molek\u00fcler y\u00f6ntem, malign h\u00fccrelerin \u00f6l\u00fcm\u00fcyle kana kar\u0131\u015fan DNA fragmanlar\u0131n\u0131n tespitine dayan\u0131yor ve geleneksel g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemleri veya doku biyopsilerinde genellikle g\u00f6zden ka\u00e7an t\u00fcm\u00f6r dinamiklerini ger\u00e7ek zamanl\u0131 olarak izleyebilme imkan\u0131 sunuyor.<\/p>\n
\u00c7al\u0131\u015fma, NYU Langone\u2019un Perlmutter Kanser Merkezi\u2019nde g\u00f6rev yapan ara\u015ft\u0131rmac\u0131lar taraf\u0131ndan \u00f6ncelikle evre III melanoma hastalar\u0131 \u00fczerinde y\u00fcr\u00fct\u00fcld\u00fc. Bu evre, kanser h\u00fccrelerinin, implant oldu\u011fu birincil deri lezyonundan \u00e7\u0131karak b\u00f6lgesel lenf nodlar\u0131na ilerledi\u011fi ara safhay\u0131 temsil ediyor. S\u00f6z konusu evre, hastalar\u0131n ya\u015fam s\u00fcresi ve tedavi yan\u0131t\u0131n\u0131n daha belirsiz oldu\u011fu ve bir\u00e7ok zorluk bar\u0131nd\u0131ran kritik bir d\u00f6nemdir. \u00c7al\u0131\u015fmaya kat\u0131lan bu hastalarda, adjuvan tedavilere ba\u015flamadan \u00f6nce \u00f6l\u00e7\u00fclebilir ctDNA tespit edilen hastalar\u0131n yakla\u015f\u0131k y\u00fczde 80\u2019inin kanserleri, tedavi alan ancak ctDNA\u2019s\u0131 tespit edilemeyenlere k\u0131yasla d\u00f6rt kat daha h\u0131zl\u0131 tekrar n\u00fcks etti.<\/p>\n
ctDNA\u2019n\u0131n sadece varl\u0131\u011f\u0131 de\u011fil, miktar\u0131n\u0131n da kanserin seyri ve tekrarlama s\u00fcresi ile do\u011frudan ili\u015fkili oldu\u011funa dikkat \u00e7ekildi. Adjuvan tedavi \u00f6ncesi ve tedavi s\u00fcresince kan dola\u015f\u0131m\u0131ndaki ctDNA seviyeleri y\u00fcksek olan hastalar\u0131n, t\u00fcm\u00f6r\u00fcn daha h\u0131zl\u0131 bir \u015fekilde geri d\u00f6nd\u00fc\u011f\u00fc belirlendi. Bu durum, ctDNA\u2019n\u0131n sadece basit bir biyobelirte\u00e7 olarak de\u011fil, t\u00fcm\u00f6r y\u00fck\u00fc ve agresifli\u011finin daha ince bir g\u00f6stergesi olarak da i\u015fe yarayabilece\u011fini ortaya koydu. Bu bulgular, hastalar\u0131n tedavi s\u00fcrecinin gereksinimlerine g\u00f6re dinamik \u015fekilde izlenip tedavi protokollerinin ona g\u00f6re ayarlanabilece\u011fi yeni bir d\u00f6nemin kap\u0131lar\u0131n\u0131 aral\u0131yor.<\/p>\n
NYU Grossman T\u0131p Fak\u00fcltesi Dermatoloji Anabilim Dal\u0131 ara\u015ft\u0131rmac\u0131lar\u0131ndan Mahrukh Syeda, MS, ctDNA tan\u0131mlamas\u0131n\u0131n, hastalar\u0131n imm\u00fcnoterapi veya hedefe y\u00f6nelik ajanlara yan\u0131t verip vermeyece\u011fini \u00f6nceden \u00f6ng\u00f6rebilmek a\u00e7\u0131s\u0131ndan klinik karar alma s\u00fcre\u00e7lerinde devrim yaratabilece\u011fini vurgulad\u0131. Bu molek\u00fcler analizler, BT ya da r\u00f6ntgen gibi anatomik de\u011fi\u015fikliklere dayal\u0131 geleneksel g\u00f6r\u00fcnt\u00fcleme tekniklerinden farkl\u0131 olarak, t\u00fcm\u00f6r\u00fcn molek\u00fcler ayak izlerini yakalayarak \u00e7ok daha erken uyar\u0131lar veriyor.<\/p>\n
\u00d6zellikle, tedavi alt\u0131nda ctDNA\u2019n\u0131n tekrar tespit edilmesinin \u00fc\u00e7, alt\u0131, dokuz veya on iki aylarda hastal\u0131\u011f\u0131n n\u00fcks edece\u011finin neredeyse kesin bir g\u00f6stergesi oldu\u011fu ortaya kondu. Tedavi ba\u015flang\u0131c\u0131nda negatif olan ctDNA seviyelerinin daha sonra y\u00fckselmesi, minimal rezid\u00fcel hastal\u0131k ya da tedavi direncine dair molek\u00fcler bir alarm g\u00f6revi g\u00f6r\u00fcyor ve radyolojik bulgulardan \u00e7ok \u00f6nce hastal\u0131\u011f\u0131n yeniden aktifle\u015fti\u011finin i\u015fareti olarak kabul ediliyor. Bu \u00f6zelli\u011fi sayesinde, hasta y\u00f6netimi daha proaktif bir hale gelebilecek ve tedavi stratejileri n\u00fcks \u00f6ncesinde zaman\u0131nda ve etkili \u015fekilde de\u011fi\u015ftirilerek ya\u015fam kalitesi art\u0131r\u0131labilecek.<\/p>\n
Evre III melanoma, ameliyatla etkilenen lenf nodlar\u0131n\u0131n \u00e7\u0131kar\u0131lmas\u0131n\u0131n ard\u0131ndan bile mikroskobik hastal\u0131\u011f\u0131n kalabilmesi nedeniyle ayr\u0131 bir zorluk te\u015fkil ediyor. Bu durum, standart g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemlerinin bir\u00e7ok kez saptayamad\u0131\u011f\u0131 hastal\u0131\u011f\u0131n gizli seyri anlam\u0131na geliyor. Bu nedenle ctDNA gibi hassas, invazif olmayan biyobelirte\u00e7lerin geli\u015ftirilmesi, hastal\u0131\u011f\u0131n erken tespiti ve zaman\u0131nda m\u00fcdahalesi i\u00e7in kritik \u00f6nem ta\u015f\u0131yor. Kanser h\u00fccrelerinin apoptotik ya da nekrotik \u00f6l\u00fcm\u00fc s\u0131ras\u0131nda kana kar\u0131\u015fan DNA par\u00e7alar\u0131n\u0131n yo\u011funlu\u011funu \u00f6l\u00e7en bu y\u00f6ntem, hastal\u0131\u011f\u0131n varl\u0131\u011f\u0131n\u0131 kesin olarak g\u00f6sterebiliyor.<\/p>\n
Ara\u015ft\u0131rmada kullan\u0131lan ctDNA testi, BRAFV600 mutasyonunu tespit eden damlac\u0131k dijital PCR teknolojisine dayan\u0131yor. Bu mutasyon, melanomun en s\u0131k g\u00f6r\u00fclen genetik s\u00fcr\u00fcc\u00fclerinden biri olarak kabul ediliyor. Mutasyona sahip t\u00fcm\u00f6r h\u00fccrelerinden kana ge\u00e7en DNA par\u00e7as\u0131, say\u0131sal olarak \u00f6l\u00e7\u00fcl\u00fcyor ve b\u00f6ylece yaln\u0131zca t\u00fcm\u00f6r varl\u0131\u011f\u0131 tescil edilmekle kalm\u0131yor, ayn\u0131 zamanda ki\u015fiye \u00f6zg\u00fc molek\u00fcler bilgi elde edilerek ki\u015fiselle\u015ftirilmi\u015f tedavi anlay\u0131\u015f\u0131 destekleniyor.<\/p>\n
ctDNA kullan\u0131m\u0131, daha \u00f6nce kolorektal ve meme kanserlerinde tedavi yan\u0131t\u0131n\u0131n de\u011ferlendirilmesi ve minimal rezid\u00fcel hastal\u0131\u011f\u0131n izlenmesi amac\u0131yla ba\u015far\u0131l\u0131 \u015fekilde uygulanm\u0131\u015ft\u0131. NYU Langone Health\u2019in 2021\u2019de yay\u0131mlad\u0131\u011f\u0131 ba\u015fka bir \u00e7al\u0131\u015fma ise ileri (evre IV) melanoma hastalar\u0131nda y\u00fcksek ctDNA seviyelerinin k\u00f6t\u00fcle\u015fen sa\u011fkal\u0131m sonu\u00e7lar\u0131yla ba\u011flant\u0131l\u0131 oldu\u011funu g\u00f6stermi\u015fti. Bu yeni \u00e7al\u0131\u015fmada ise yakla\u015f\u0131k 600 hastan\u0131n yer ald\u0131\u011f\u0131 \u00e7ok k\u0131tal\u0131 bir klinik denemede ctDNA\u2019n\u0131n evre III melanoma takibinde de g\u00fcvenilirli\u011fi ve prognostik de\u011feri onayland\u0131.<\/p>\n
\u00c7ok uluslu ara\u015ft\u0131rmada Avrupa, Kuzey Amerika ve Avustralya\u2019da tedavi g\u00f6ren hastalar\u0131n ctDNA verileri klinik n\u00fcks kan\u0131tlar\u0131yla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131. Tedavi, demografi ve di\u011fer de\u011fi\u015fkenler dikkate al\u0131narak yap\u0131lan analizler, ctDNA\u2019n\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 \u00f6l\u00e7en di\u011fer biyobelirte\u00e7lerden \u00fcst\u00fcn oldu\u011funu ortaya koydu. Bu bulgu, ctDNA testlerinin t\u00fcm\u00f6r varl\u0131\u011f\u0131n\u0131 do\u011frudan ve \u00f6zg\u00fcl bi\u00e7imde yans\u0131tmas\u0131 a\u00e7\u0131s\u0131ndan \u00f6nemli bir avantaj sa\u011fl\u0131yor.<\/p>\n
NYU Langone\u2019dan deneyimli dermatolog ve k\u0131demli yazar David Polsky, MD, PhD, biyopsilerle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda ctDNA testinin hastal\u0131k durumunu ger\u00e7ek zamanl\u0131 ve kesin molek\u00fcler sinyallerle g\u00f6sterebildi\u011fini ifade etti. Ancak, ba\u015flang\u0131\u00e7ta ctDNA\u2019s\u0131 negatif olan baz\u0131 hastalarda yine de n\u00fcks g\u00f6zlenmesinin de g\u00f6z ard\u0131 edilmemesi gerekti\u011fini vurgulayarak testin duyarl\u0131l\u0131\u011f\u0131n\u0131n art\u0131r\u0131lmas\u0131 y\u00f6n\u00fcnde \u00e7al\u0131\u015fmalar\u0131n s\u00fcrece\u011fini s\u00f6yledi.<\/p>\n
Ara\u015ft\u0131rman\u0131n devam eden a\u015famalar\u0131nda, ctDNA tespitinin analitik hassasiyetinin y\u00fckseltilmesi ve klinik pratikte bu biyobelirte\u00e7 bazl\u0131 takibin hasta sa\u011fkal\u0131m\u0131 ve ya\u015fam kalitesi \u00fczerindeki etkisinin titizlikle incelenmesi planlan\u0131yor. Yak\u0131n zamanda yap\u0131lacak klinik denemelerde, ctDNA sonu\u00e7lar\u0131n\u0131n ger\u00e7ek zamanl\u0131 geri bildirim olarak terap\u00f6tik kararlar\u0131 nas\u0131l etkileyebilece\u011fi \u00f6zellikle ele al\u0131nacak. Bu sayede adjuvan tedavilerin hastal\u0131\u011f\u0131n mevcut durumuna g\u00f6re zaman\u0131nda art\u0131r\u0131lmas\u0131 veya azalt\u0131lmas\u0131 m\u00fcmk\u00fcn olacak.<\/p>\n
Ara\u015ft\u0131rma Novartis Pharmaceuticals taraf\u0131ndan desteklendi ve ila\u00e7 sekt\u00f6r\u00fcn\u00fcn ki\u015fiselle\u015ftirilmi\u015f onkoloji alan\u0131nda likit biyopsi uygulamalar\u0131na artan ilgisinin g\u00f6stergesi olarak de\u011ferlendirildi. Kaynaklar\u0131n finansman\u0131 ve dan\u0131\u015fmanl\u0131k rolleri a\u00e7\u0131k ve \u015feffaf bi\u00e7imde beyan edilerek, bilimsel ba\u011f\u0131ms\u0131zl\u0131k ve etik standartlar titizlikle korundu.<\/p>\n
Bu geli\u015fme, melanoma bak\u0131m\u0131nda molek\u00fcler izleme \u00e7a\u011f\u0131n\u0131 ba\u015flat\u0131yor. ctDNA arac\u0131l\u0131\u011f\u0131yla hastalar\u0131n ve klinisyenlerin, hastal\u0131k n\u00fcks\u00fcn\u00fc klinik belirtiler ortaya \u00e7\u0131kmadan \u00f6nce tespit etme \u015fans\u0131 art\u0131yor. Kanserin sessiz molek\u00fcler \u201cf\u0131s\u0131lt\u0131lar\u0131n\u0131\u201d yakalayan bu y\u00f6ntem, tedaviye erken m\u00fcdahale avantaj\u0131 sa\u011flayarak hayat kurtar\u0131c\u0131 bir d\u00f6n\u00fc\u015f\u00fcm vaat ediyor.<\/p>\n
—<\/p>\n
**Ara\u015ft\u0131rma Konusu**:
\nMelanom hastalar\u0131nda ameliyat sonras\u0131 adjuvan tedavi alan hastalar\u0131n kan dola\u015f\u0131m\u0131nda BRAFV600 mutasyonlu ctDNA\u2019n\u0131n tespitinin rek\u00fcrrens \u00f6ng\u00f6r\u00fcs\u00fcnde klinik validasyonu.<\/p>\n
**Makale Ba\u015fl\u0131\u011f\u0131**:
\nClinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial<\/p>\n
**Haberin Yay\u0131n Tarihi**:
\n15 Nisan 2025<\/p>\n
**Web References**:
\n10.1016\/S1470-2045(25)00139-1<\/p>\n
**Anahtar Kelimeler**:
\nMelanom, Kanser tedavileri, Klinik ara\u015ft\u0131rma, Kanser ara\u015ft\u0131rmalar\u0131, Deri t\u00fcm\u00f6rleri, Kanser hastalar\u0131, Dermatoloji, DNA par\u00e7ac\u0131klar\u0131, ctDNA izlemi, BRAFV600 mutasyonu, Erken n\u00fcks tespiti, Molek\u00fcler tan\u0131 y\u00f6ntemleri, NYU Langone Health<\/p>\n","protected":false},"excerpt":{"rendered":"
NYU Langone Health b\u00fcnyesindeki bilim insanlar\u0131, agresif seyreden deri kanseri melanoman\u0131n tedavisinde umut vadeden \u00f6nemli bir geli\u015fmeye imza att\u0131. Ara\u015ft\u0131rmac\u0131lar, hastalar\u0131n kan dola\u015f\u0131m\u0131nda bulunan t\u00fcm\u00f6r kaynakl\u0131 DNA par\u00e7ac\u0131klar\u0131n\u0131n (ctDNA) takibinin, kanserin n\u00fcks etme olas\u0131l\u0131\u011f\u0131n\u0131 y\u00fcksek do\u011frulukla tahmin edebilece\u011fini ortaya koydu. Bu molek\u00fcler y\u00f6ntem, malign h\u00fccrelerin \u00f6l\u00fcm\u00fcyle kana kar\u0131\u015fan DNA fragmanlar\u0131n\u0131n tespitine dayan\u0131yor ve geleneksel g\u00f6r\u00fcnt\u00fcleme…<\/p>\n","protected":false},"author":1,"featured_media":2683,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[284,283,281,285,282],"tmauthors":[],"class_list":{"0":"post-2682","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-adjuvan-tedavi-oncesi-ctdna-olcumu","9":"tag-evre-iii-melanom-tedavi-izleme","10":"tag-melanom-erken-nuksu-gen-temelli-kan-testi","11":"tag-molekuler-biyobelirteclerle-kanser-nuksu-tahmini","12":"tag-tumor-kaynakli-dna-ctdna-takibi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Melanom-Erken-Nuksu-icin-Gen-Temelli-Kan-Testi-1744760702.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/2682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=2682"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/2682\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/2683"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=2682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=2682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=2682"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=2682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}